{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:54:14Z","timestamp":1782993254541,"version":"3.54.5"},"reference-count":20,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Treatment of psoriatic nail is difficult.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> The aim of this study was to evaluate and compare the efficacy and safety of methotrexate and cyclosporine in psoriatic nail.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Thirty\u2010seven psoriatic patients with nail involvement were randomized to treatment with methotrexate (initial dose, 15\u2003mg per week) or cyclosporine (initial dose, 5\u2003mg per kg of bodyweight per day) for 24\u2003weeks. The primary outcome was the Nail Psoriasis Severity Index (NAPSI). The Psoriasis Area and Severity Index (PASI), doctor and patient global score were also measured. The scores were determined by a blinded observer.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Seventeen patients completed the study in each group. The mean percentages of reduction of the NAPSI score after methotrexate and cyclosporine treatments were 43.3% and 37.2%, respectively. No significant differences between the treatment groups was found for in the NAPSI, PASI, physician\u2019s and patient\u2019s global score at the end of the study period. The methotrexate group showed a significant improvement in nail matrix scores and the cyclosporine group in nail bed score.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Moderate effectiveness on psoriatic nail was found in the two treatment agents and there were no significant differences in efficacy between the groups. A significant improvement was detected in methotrexate group for the nail matrix findings, and in cyclosporine group for the nail bed findings.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2010.03927.x","type":"journal-article","created":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T07:49:40Z","timestamp":1291189780000},"page":"1080-1084","source":"Crossref","is-referenced-by-count":75,"title":["Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one\u2010blind, randomized study"],"prefix":"10.1111","volume":"25","author":[{"given":"M.","family":"G\u00fcm\u00fc\u015fel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130.","family":"Mevlito\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bodur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.07.073"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2000.00663.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0686-5"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08686.x"},{"key":"e_1_2_5_6_2","first-page":"1452","article-title":"Therapies for psoriatic nail disease: a systematic review","volume":"31","author":"Cassel S","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2008.600"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/120347540400800208"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.027"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021359"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2009.00027"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2008.08012"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2008.12.003"},{"key":"e_1_2_5_15_2","first-page":"248","article-title":"Successful treatment of psoriatic nails with low \u2013dose cyclosporine administration","volume":"17","author":"Syuto T","year":"2007","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90189-2"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(05)70180-7"},{"key":"e_1_2_5_18_2","first-page":"355","article-title":"Tazoratene 0. 1% gel in the treatment of fingernail psoriasis: a double\u2010blind, randomized, vehicle\u2010controlled study","volume":"68","author":"Cher RK","year":"2001","journal-title":"Cutis"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00112.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.09.012"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.042"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2010.03927.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2010.03927.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:24:51Z","timestamp":1697387091000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2010.03927.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1468-3083.2010.03927.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03927.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}